As a result, LSC and AML blasts can be eradicated at largest extent by the cCART and in vitro, the cCART showed specific and potent anti-leukemia efficacy against CLL-1 or CD33-positive on both AML cell lines and primary AML cells. Here, CD33 is linked to leukemia.